<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2024-3-2424</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2473</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Антибактериальное действие оксида азота на возбудители госпитальной пневмонии (экспериментальное исследование)</article-title><trans-title-group xml:lang="en"><trans-title>Antibacterial Effect of Nitric Oxide on the Causative Agents of Hospital-Acquired Pneumonia (Experimental Study)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калашникова</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalashnikova</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калашникова Татьяна Петровна</p><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Tatiana P. Kalashnikova</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><email xlink:type="simple">Kalashnikova-t@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арсеньева</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Arsenyeva</surname><given-names>Iu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Iulia A. Arsenyeva</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каменщиков</surname><given-names>Н. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamenshchikov</surname><given-names>N. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Nikolay O. Kamenshchikov</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подоксенов</surname><given-names>Ю. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Podoksenov</surname><given-names>Yu. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Yuri K. Podoksenov</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравченко</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchenko</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Igor V. Kravchenko</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чубик</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chubik</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634050, г. Томск, Московский тракт, д. 2</p></bio><bio xml:lang="en"><p>Marianna V. Chubik</p><p>2 Moskovsky tract, 634050 Tomsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпова</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpova</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634050, г. Томск, Московский тракт, д. 2</p></bio><bio xml:lang="en"><p>Mariia R. Karpova</p><p>2 Moskovsky tract, 634050 Tomsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мышова</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Myshova</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634050, г. Томск, Московский тракт, д. 2</p></bio><bio xml:lang="en"><p>Alexandra E. Myshova</p><p>2 Moskovsky tract, 634050 Tomsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Быконя</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bykonia</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634063, г. Томск, ул. И. Черных, д. 96</p></bio><bio xml:lang="en"><p>Svetlana A. Bykonia</p><p>96 I. Chernykh Str., 634063 Tomsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ракитин</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakitin</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634063, г. Томск, ул. И. Черных, д. 96</p></bio><bio xml:lang="en"><p>Sergei S. Rakitin</p><p>96 I. Chernykh Str., 634063 Tomsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козулин</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozulin</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Maksim S. Kozulin </p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Козлов</surname><given-names>Б. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kozlov</surname><given-names>B. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Boris N. Kozlov</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бощенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Boshchenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>634012, г. Томск, ул. Киевская, д. 111А</p></bio><bio xml:lang="en"><p>Alla A. Boshchenko</p><p>111A Kievskaya Str., 634012 Tomsk</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Cardiology, Tomsk National Research Medical Center, Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Томская областная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk Regional Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>29</day><month>05</month><year>2024</year></pub-date><volume>20</volume><issue>3</issue><fpage>32</fpage><lpage>41</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калашникова Т.П., Арсеньева Ю.А., Каменщиков Н.О., Подоксенов Ю.К., Кравченко И.В., Чубик М.В., Карпова М.Р., Мышова А.Е., Быконя С.А., Ракитин С.С., Козулин М.С., Козлов Б.Н., Бощенко А.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Калашникова Т.П., Арсеньева Ю.А., Каменщиков Н.О., Подоксенов Ю.К., Кравченко И.В., Чубик М.В., Карпова М.Р., Мышова А.Е., Быконя С.А., Ракитин С.С., Козулин М.С., Козлов Б.Н., Бощенко А.А.</copyright-holder><copyright-holder xml:lang="en">Kalashnikova T.P., Arsenyeva I.A., Kamenshchikov N.O., Podoksenov Y.K., Kravchenko I.V., Chubik M.V., Karpova M.R., Myshova A.E., Bykonia S.A., Rakitin S.S., Kozulin M.S., Kozlov B.N., Boshchenko A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2473">https://www.reanimatology.com/rmt/article/view/2473</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: оценить антимикробное действие оксида азота (NO) in vitro при однократном и многократном воздействии на основные возбудители внутрибольничной пневмонии, выделенные из мокроты кардиохирургических пациентов.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: Суточную культуру микроорганизмов из панрезистентных изолятов Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii и Klebsiella pneumoniae, выделенных из мокроты стационарных кардиохирургических пациентов с внутрибольничной пневмонией, а также музейные культуры P. aeruginosa и E. coli из Американской коллекции типовых культур подвергали воздействию NO в дозе 200 ppm в герметичной камере в течение 30 минут (экспериментальный образец) или медицинского воздуха (контрольный образец). После однократного либо 4-кратного с интервалом в 4 часа воздействия газов чашки Петри помещали в термостат при температуре 37°C, результаты оценивали через 24, 48 ч либо через 12, 24, 36 и 48 ч соответственно. Выращенные колонии подсчитывали с помощью автоматического счетчика колоний. Результаты выражали в КОЕ/мл.</p></sec><sec><title>Результаты</title><p>Результаты: Через 24 и 48 часов после однократного воздействия NO ни в одном случае не наблюдали роста клинических изолятов P. aeruginosa и E. coli. Рост A. baumannii был меньше по сравнению с контролем через 24 часа, но его непрерывный рост отметили через 48 часов. Эффекта NO в дозе 200 ppm при однократном воздействии на другие микроорганизмы не обнаружили. После 4 воздействий NO рост музейной культуры E. coli так и не обнаружили, рост других экспериментальных штаммов был значительно снижен по сравнению с контролем (р&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Представленные результаты могут служить предпосылкой начала применения многократной прерывистой ингаляционной NO-терапии в дозе 200 ppm при лечении пациентов с внутрибольничной бактериальной пневмонией.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to evaluate the antimicrobial effect of single and repeated nitric oxide (NO) exposure on the major pathogens of nosocomial pneumonia isolated from the sputum of cardiac surgery patients.</p><sec><title>Materials and Methods</title><p>Materials and Methods. A 24-hour culture of microorganisms from pan-resistant isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, and Klebsiella pneumoniae from the sputum of inpatient cardiac surgery patients with nosocomial pneumonia, as well as strains of P. aeruginosa and E. coli from the American Type Culture Collection (ATCC), were exposed to 200 ppm NO (experimental sample) or medical air (control sample) in a sealed chamber for 30 minutes. After a single or 4 repeated gas exposure at 4 h intervals, Petri dishes were placed in a thermostat at 37°C and the results were evaluated at 24 and 48 h or at 12, 24, 36 and 48 h, respectively. Grown colonies were counted using an automated colony counter and recorded as CFU/mL.</p></sec><sec><title>Results</title><p>Results. No growth of clinical isolates of P. aeruginosa and E. coli was observed 24 and 48 h after a single exposure to NO. Growth of A. baumannii was lower compared to controls at 24 h but continued at 48 h. No effect of a single exposure to 200 ppm NO on other microorganisms was observed. After 4 exposures to NO, the growth of ATCC E. coli was not detected, the growth of other experimental strains was significantly lower compared to the control (P&lt;0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. Our results provide a rationale for the use of multiple intermittent inhalation of 220 ppm NO for the treatment of patients with hospital-acquired bacterial pneumonia.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>оксид азота</kwd><kwd>NO</kwd><kwd>Acinetobacter baumannii</kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>Escherichia coli</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>госпитальная пневмония</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nitric oxide</kwd><kwd>NO</kwd><kwd>Acinetobacter baumannii</kwd><kwd>Pseudomonas aeruginosa</kwd><kwd>Escherichia coli</kwd><kwd>Klebsiella pneumoniae</kwd><kwd>hospital-acquired pneumonia</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках государственного задания № 122123000017-3.</funding-statement><funding-statement xml:lang="en">The work was carried out under the government order No. 122123000017-3</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for Disease Control and Prevention Home Page (U.S.) (2019). Antibiotic resistance threats in the United States, 2019. Available online https://www.cdc.gov/drugresistance/biggest-threats.html (accessed on 19 July 2023).</mixed-citation><mixed-citation xml:lang="en">Centers for Disease Control and Prevention Home Page (U.S.) (2019). Antibiotic resistance threats in the United States, 2019. Available online https://www.cdc.gov/drugresistance/biggest-threats.html (accessed on 19 July 2023).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization home page. No time to wait: securing the future from drug-resistant infection. Available online https://www.who.int/publications/i/item/no-timeto-wait-securing-the-future-from-drug-resistant-infections (accessed on 19 July 2023).</mixed-citation><mixed-citation xml:lang="en">World Health Organization home page. No time to wait: securing the future from drug-resistant infection. Available online https://www.who.int/publications/i/item/no-timeto-wait-securing-the-future-from-drug-resistant-infections (accessed on 19 July 2023).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jean S.S., Gould I.M., Lee W.S., Hsueh P.R., International Society of Antimicrobial Chemotherapy (ISAC). New drugs for multidrug-resistant gram-negative organisms: time for stewardship. Drugs. 2019; 79 (7): 705–714. DOI: 10.1007/s40265-019-01112-1. PMID: 30972660.</mixed-citation><mixed-citation xml:lang="en">Jean S.S., Gould I.M., Lee W.S., Hsueh P.R., International Society of Antimicrobial Chemotherapy (ISAC). New drugs for multidrug-resistant gram-negative organisms: time for stewardship. Drugs. 2019; 79 (7): 705–714. DOI: 10.1007/s40265-019-01112-1. PMID: 30972660.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization home page. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed on 19 July 2023).</mixed-citation><mixed-citation xml:lang="en">World Health Organization home page. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed on 19 July 2023).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hovan M.R., Narayanan N., Cedarbaum V., Bhowmick T., Kirn T.J. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia. Diagn Microbiol Infect Dis. 2021; 101 (4): 115505. DOI: 10.1016/j.diagmicrobio.2021.115505. PMID: 34399381.</mixed-citation><mixed-citation xml:lang="en">Hovan M.R., Narayanan N., Cedarbaum V., Bhowmick T., Kirn T.J. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia. Diagn Microbiol Infect Dis. 2021; 101 (4): 115505. DOI: 10.1016/j.diagmicrobio.2021.115505. PMID: 34399381.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022; 10 (2): 369. DOI: 10.3390/biomedicines10020369. PMID: 35203578.</mixed-citation><mixed-citation xml:lang="en">Kamenshchikov N.O., Berra L., Carroll R.W. Therapeutic effects of inhaled nitric oxide therapy in COVID-19 patients. Biomedicines. 2022; 10 (2): 369. DOI: 10.3390/biomedicines10020369. PMID: 35203578.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kamenshchikov N.O., Kozlov B.N., Dish A.Y., Podoksenov Y.K., Anfinogenova Y.D., Boshchenko A.A., Safaee B., et al. A safety study of intermittent versus continuous inhaled NO therapy in spontaneously breathing COVID-19 patients: a randomized controlled trial. Circulation 2021; 144 (Suppl 1). ID: covidwho-1633798.</mixed-citation><mixed-citation xml:lang="en">Kamenshchikov N.O., Kozlov B.N., Dish A.Y., Podoksenov Y.K., Anfinogenova Y.D., Boshchenko A.A., Safaee B., et al. A safety study of intermittent versus continuous inhaled NO therapy in spontaneously breathing COVID-19 patients: a randomized controlled trial. Circulation 2021; 144 (Suppl 1). ID: covidwho-1633798.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Fakhr B.S., Di Fenza R., Gianni S., Wiegand S.B., Miyazaki Y., Morais C.C.A., Gibson L.E., et al., Nitric Oxide Study Investigators. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021; 116: 7–13. DOI: 10.1016/j.niox.2021.08.003. PMID: 34400339.</mixed-citation><mixed-citation xml:lang="en">Fakhr B.S., Di Fenza R., Gianni S., Wiegand S.B., Miyazaki Y., Morais C.C.A., Gibson L.E., et al., Nitric Oxide Study Investigators. Inhaled high dose nitric oxide is a safe and effective respiratory treatment in spontaneous breathing hospitalized patients with COVID-19 pneumonia. Nitric Oxide. 2021; 116: 7–13. DOI: 10.1016/j.niox.2021.08.003. PMID: 34400339.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Parikh R., Wilson C., Weinberg J., Gavin D., Murphy J., Reardon C.C. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther Adv Respir Dis. 2020; 14: 1753466620933510. DOI: 10.1177/1753466620933510. PMID: 32539647.</mixed-citation><mixed-citation xml:lang="en">Parikh R., Wilson C., Weinberg J., Gavin D., Murphy J., Reardon C.C. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Ther Adv Respir Dis. 2020; 14: 1753466620933510. DOI: 10.1177/1753466620933510. PMID: 32539647.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lei C., Su B., Dong H., Bellavia A., Di Fenza R., Fakhr B.S., Gianni S., et al. Protocol of a randomized controlled trial testing inhaled nitric oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-COV-2). medRxov. Preprint. 2020: 03.09.20033530. DOI: 10.1101/2020.03.09.20033530. PMID: 32511534.</mixed-citation><mixed-citation xml:lang="en">Lei C., Su B., Dong H., Bellavia A., Di Fenza R., Fakhr B.S., Gianni S., et al. Protocol of a randomized controlled trial testing inhaled nitric oxide in mechanically ventilated patients with severe acute respiratory syndrome in COVID-19 (SARS-COV-2). medRxov. Preprint. 2020: 03.09.20033530. DOI: 10.1101/2020.03.09.20033530. PMID: 32511534.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fakhr B.S., Wiegand S.B., Pinciroli R., Gianni S., Morais C.C.A., Ikeda T., Miyazaki Y., et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe soronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020; 136 (6): 1109-1113. DOI: 10.1097/AOG.0000000000004128. PMID: 32852324.</mixed-citation><mixed-citation xml:lang="en">Fakhr B.S., Wiegand S.B., Pinciroli R., Gianni S., Morais C.C.A., Ikeda T., Miyazaki Y., et al. High concentrations of nitric oxide inhalation therapy in pregnant patients with severe soronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020; 136 (6): 1109-1113. DOI: 10.1097/AOG.0000000000004128. PMID: 32852324.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sodano F., Gazzano E., Fruttero R., Lazzarato L. NO in viral infections: role and development of antiviral therapies. Molecules. 2022; 27 (7): 2337. DOI: 10.3390/molecules27072337. PMID: 35408735.</mixed-citation><mixed-citation xml:lang="en">Sodano F., Gazzano E., Fruttero R., Lazzarato L. NO in viral infections: role and development of antiviral therapies. Molecules. 2022; 27 (7): 2337. DOI: 10.3390/molecules27072337. PMID: 35408735.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lisi F., Zelikin A.N., Chandrawati R. Nitric oxide to fight viral infections. Adv Sci (Weinh). 2021; 8 (7): 2003895. DOI: 10.1002/advs.202003895. PMID: 33850691.</mixed-citation><mixed-citation xml:lang="en">Lisi F., Zelikin A.N., Chandrawati R. Nitric oxide to fight viral infections. Adv Sci (Weinh). 2021; 8 (7): 2003895. DOI: 10.1002/advs.202003895. PMID: 33850691.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Akaberi D., Krambrich J., Ling J., Luni C., Hedenstierna G., Järhult J.D., Lennerstrand J., et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol. 2020; 37: 101734. DOI: 10.1016/j.redox.2020.101734. PMID: 33007504.</mixed-citation><mixed-citation xml:lang="en">Akaberi D., Krambrich J., Ling J., Luni C., Hedenstierna G., Järhult J.D., Lennerstrand J., et al. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Redox Biol. 2020; 37: 101734. DOI: 10.1016/j.redox.2020.101734. PMID: 33007504.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Pieretti J.C., Rubilar O., Weller R.B., Tortella G.R., Seabra A.B. Nitric oxide (NO) and nanoparticles — potential small tools for the war against COVID-19 and other human coronavirus infections. Virus Res. 2021; 291: 198202. DOI: 10.1016/j.virusres.2020.198202. PMID: 33086123.</mixed-citation><mixed-citation xml:lang="en">Pieretti J.C., Rubilar O., Weller R.B., Tortella G.R., Seabra A.B. Nitric oxide (NO) and nanoparticles — potential small tools for the war against COVID-19 and other human coronavirus infections. Virus Res. 2021; 291: 198202. DOI: 10.1016/j.virusres.2020.198202. PMID: 33086123.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fang W., Jiang J., Su L., Shu T., Liu H., Lai S., Ghiladi R.A., et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med. 2021; 163: 153–162. DOI: 10.1016/j.freeradbiomed.2020.12.008. PMID: 33347987.</mixed-citation><mixed-citation xml:lang="en">Fang W., Jiang J., Su L., Shu T., Liu H., Lai S., Ghiladi R.A., et al. The role of NO in COVID-19 and potential therapeutic strategies. Free Radic Biol Med. 2021; 163: 153–162. DOI: 10.1016/j.freeradbiomed.2020.12.008. PMID: 33347987.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Oza P.P., Kashfi K. Utility of NO and H2S donating platforms in managing COVID-19: rationale and promise. Nitric Oxide. 2022; 128: 72–102. DOI: 10.1016/j.niox.2022.08.003. PMID: 36029975.</mixed-citation><mixed-citation xml:lang="en">Oza P.P., Kashfi K. Utility of NO and H2S donating platforms in managing COVID-19: rationale and promise. Nitric Oxide. 2022; 128: 72–102. DOI: 10.1016/j.niox.2022.08.003. PMID: 36029975.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chavda V.P., Patel A.B., Vora L.K., Singla R.K., Shah P., Uversky V.N., Apostolopoulos V. Nitric oxide and its derivatives containing nasal spray and inhalation therapy for the treatment of COVID-19. Curr Pharm Des. 2022; 28 (46): 3658–3670. DOI: 10.2174/1381612829666221024124848. PMID: 36284382.</mixed-citation><mixed-citation xml:lang="en">Chavda V.P., Patel A.B., Vora L.K., Singla R.K., Shah P., Uversky V.N., Apostolopoulos V. Nitric oxide and its derivatives containing nasal spray and inhalation therapy for the treatment of COVID-19. Curr Pharm Des. 2022; 28 (46): 3658–3670. DOI: 10.2174/1381612829666221024124848. PMID: 36284382.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Malone-Povolny M.J., Maloney S.E., Schoenfisch M.H. Nitric oxide therapy for diabetic wound healing. Adv Healthc Mater. 2019; 8 (12): e1801210. DOI: 10.1002/adhm.201801210. PMID: 30645055.</mixed-citation><mixed-citation xml:lang="en">Malone-Povolny M.J., Maloney S.E., Schoenfisch M.H. Nitric oxide therapy for diabetic wound healing. Adv Healthc Mater. 2019; 8 (12): e1801210. DOI: 10.1002/adhm.201801210. PMID: 30645055.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kletschkus K., Haralambiev L., Mustea A., Bekeschus S., Stope M.B. Review of innovative physical therapy methods: introduction to the principles of cold physical plasma. In Vivo. 2020; 34 (6): 3103–3107. DOI: 10.21873/invivo.12143. PMID: 33144413.</mixed-citation><mixed-citation xml:lang="en">Kletschkus K., Haralambiev L., Mustea A., Bekeschus S., Stope M.B. Review of innovative physical therapy methods: introduction to the principles of cold physical plasma. In Vivo. 2020; 34 (6): 3103–3107. DOI: 10.21873/invivo.12143. PMID: 33144413.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shekhter A.B., Pekshev A.V., Vagapov A.B., Telpukhov V.I., Panyushkin P.V., Rudenko T.G., Fayzullin A.L., et al. Physicochemical parameters of NO-containing gas flow affect wound healing therapy. An experimental study. Eur J Pharm Sci. 2019; 128: 193–201. DOI: 10.1016/j.ejps.2018.11.034. PMID: 30543840.</mixed-citation><mixed-citation xml:lang="en">Shekhter A.B., Pekshev A.V., Vagapov A.B., Telpukhov V.I., Panyushkin P.V., Rudenko T.G., Fayzullin A.L., et al. Physicochemical parameters of NO-containing gas flow affect wound healing therapy. An experimental study. Eur J Pharm Sci. 2019; 128: 193–201. DOI: 10.1016/j.ejps.2018.11.034. PMID: 30543840.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Pekshev A.V., Shekhter A.B., Vagapov A.B., Sharapov N.A., Vanin A.F. Study of plasma-chemical NO-containing gas flow for treatment of wounds and inflammatory processes. Nitric Oxide. 2018; 73: 74–80. DOI: 10.1016/j.niox.2017.06.002. PMID: 28602888.</mixed-citation><mixed-citation xml:lang="en">Pekshev A.V., Shekhter A.B., Vagapov A.B., Sharapov N.A., Vanin A.F. Study of plasma-chemical NO-containing gas flow for treatment of wounds and inflammatory processes. Nitric Oxide. 2018; 73: 74–80. DOI: 10.1016/j.niox.2017.06.002. PMID: 28602888.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ghaffari A., Jalili R., Ghaffari M., Miller C., Ghahary A. Efficacy of gaseous nitric oxide in the treatment of skin and soft tissue infections. Wound Repair Regen. 2007; 15 (3): 368–377. DOI: 10.1111/j.1524-475X.2007.00239.x. PMID: 17537124.</mixed-citation><mixed-citation xml:lang="en">Ghaffari A., Jalili R., Ghaffari M., Miller C., Ghahary A. Efficacy of gaseous nitric oxide in the treatment of skin and soft tissue infections. Wound Repair Regen. 2007; 15 (3): 368–377. DOI: 10.1111/j.1524-475X.2007.00239.x. PMID: 17537124.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bentur L., Gur M., Ashkenazi M., Livnat-Levanon G., Mizrahi M., Tal A., Ghaffari A., et al. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J Cyst Fibros. 2020; 19 (2): 225–231. DOI: 10.1016/j.jcf.2019.05.002. PMID: 31129068.</mixed-citation><mixed-citation xml:lang="en">Bentur L., Gur M., Ashkenazi M., Livnat-Levanon G., Mizrahi M., Tal A., Ghaffari A., et al. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J Cyst Fibros. 2020; 19 (2): 225–231. DOI: 10.1016/j.jcf.2019.05.002. PMID: 31129068.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Deppisch C., Herrmann G., Graepler-Mainka U., Wirtz H., Heyder S., Engel C., Marschal M., et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection. 2016; 44 (4): 513–520. DOI: 10.1007/s15010-016-0879-x. PMID: 26861246.</mixed-citation><mixed-citation xml:lang="en">Deppisch C., Herrmann G., Graepler-Mainka U., Wirtz H., Heyder S., Engel C., Marschal M., et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection. 2016; 44 (4): 513–520. DOI: 10.1007/s15010-016-0879-x. PMID: 26861246.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hall J.R., Rouillard K.R., Suchyta D.J., Brown M.D., Ahonen M.J.R., Schoenfisc M.H. Mode of nitric oxide delivery affects antibacterial action. ACS Biomater Sci Eng. 2020; 6 (1): 433–441. DOI: 10.1021/acsbiomaterials.9b01384. PMID: 32671191.</mixed-citation><mixed-citation xml:lang="en">Hall J.R., Rouillard K.R., Suchyta D.J., Brown M.D., Ahonen M.J.R., Schoenfisc M.H. Mode of nitric oxide delivery affects antibacterial action. ACS Biomater Sci Eng. 2020; 6 (1): 433–441. DOI: 10.1021/acsbiomaterials.9b01384. PMID: 32671191.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chau T., Blade K., Da Silva J., Ghaffari A., Zelazny A., Olivier K. High efficacy of high-dose nitric oxide and its synergistic effect with antibiotics against Mycobacterium Abscessus. European Respiratory Journal. 2019; 54: OA4950. DOI: 10.1183/13993003.congress-2019.OA4950.</mixed-citation><mixed-citation xml:lang="en">Chau T., Blade K., Da Silva J., Ghaffari A., Zelazny A., Olivier K. High efficacy of high-dose nitric oxide and its synergistic effect with antibiotics against Mycobacterium Abscessus. European Respiratory Journal. 2019; 54: OA4950. DOI: 10.1183/13993003.congress-2019.OA4950.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sulemankhil I., Ganopolsky J.G., Dieni C.A., Dan A.F., Jones M.L., Prakash S. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob Agents Chemother. 2012; 56 (12): 6095–103. DOI: 10.1128/AAC.01173-12. PMID: 22948868.</mixed-citation><mixed-citation xml:lang="en">Sulemankhil I., Ganopolsky J.G., Dieni C.A., Dan A.F., Jones M.L., Prakash S. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob Agents Chemother. 2012; 56 (12): 6095–103. DOI: 10.1128/AAC.01173-12. PMID: 22948868.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Waite R.D., Stewart J.E., Stephen A.S., Allaker R.P. Activity of a nitric oxide-generating wound treatment system against wound pathogen biofilms. Int J Antimicrob Agents. 2018; 52 (3): 338–343. DOI: 10.1016/j.ijantimicag.2018.04.009. PMID: 29665443.</mixed-citation><mixed-citation xml:lang="en">Waite R.D., Stewart J.E., Stephen A.S., Allaker R.P. Activity of a nitric oxide-generating wound treatment system against wound pathogen biofilms. Int J Antimicrob Agents. 2018; 52 (3): 338–343. DOI: 10.1016/j.ijantimicag.2018.04.009. PMID: 29665443.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Howlin R.P., Cathie K., Hall-Stoodley L., Cornelius V., Duignan C., Allan R.N., Fernandez B.O., et al. Low-dose nitric oxide as targeted anti-biofilm Aadjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Mol Ther. 2017; 25 (9): 2104–2116. DOI: 10.1016/j.ymthe.2017.06.021. PMID: 28750737.</mixed-citation><mixed-citation xml:lang="en">Howlin R.P., Cathie K., Hall-Stoodley L., Cornelius V., Duignan C., Allan R.N., Fernandez B.O., et al. Low-dose nitric oxide as targeted anti-biofilm Aadjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. Mol Ther. 2017; 25 (9): 2104–2116. DOI: 10.1016/j.ymthe.2017.06.021. PMID: 28750737.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Hasan S., Albayaty Y.N.S., Thierry B., Prestidge C.A., Thomas N. Mechanistic studies of the antibiofilm activity and synergy with antibiotics of isosorbide mononitrate. Eur J Pharm Sci. 2018; 115: 50–56. DOI: 10.1016/j.ejps.2018.01.003. PMID: 29305985.</mixed-citation><mixed-citation xml:lang="en">Hasan S., Albayaty Y.N.S., Thierry B., Prestidge C.A., Thomas N. Mechanistic studies of the antibiofilm activity and synergy with antibiotics of isosorbide mononitrate. Eur J Pharm Sci. 2018; 115: 50–56. DOI: 10.1016/j.ejps.2018.01.003. PMID: 29305985.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ren H., Wu J., Colletta A., Meyerhoff M.E., Xi C. Efficient eradication of mature Pseudomonas aeruginosa biofilm via controlled delivery of nitric oxide combined with antimicrobial peptide and antibiotics. Front Microbiol. 2016; 7: 1260. DOI: 10.3389/fmicb.2016.01260. PMID: 27582732.</mixed-citation><mixed-citation xml:lang="en">Ren H., Wu J., Colletta A., Meyerhoff M.E., Xi C. Efficient eradication of mature Pseudomonas aeruginosa biofilm via controlled delivery of nitric oxide combined with antimicrobial peptide and antibiotics. Front Microbiol. 2016; 7: 1260. DOI: 10.3389/fmicb.2016.01260. PMID: 27582732.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Zemke A.C., Madison C.J., Kasturiarachi N., Pearce L.L., Peterson J. Antimicrobial synergism toward Pseudomonas aeruginosa by gallium (III) and inorganic nitrite. Front Microbiol. 2020; 11: 2113. DOI: 10.3389/fmicb.2020.02113. PMID: 32983071.</mixed-citation><mixed-citation xml:lang="en">Zemke A.C., Madison C.J., Kasturiarachi N., Pearce L.L., Peterson J. Antimicrobial synergism toward Pseudomonas aeruginosa by gallium (III) and inorganic nitrite. Front Microbiol. 2020; 11: 2113. DOI: 10.3389/fmicb.2020.02113. PMID: 32983071.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Rouillard K.R., Novak O.P., Pistiolis A.M., Yang L., Ahonen M.J.R., McDonald R.A., Schoenfisch M.H. Exogenous nitric oxide improves antibiotic susceptibility in resistant bacteria. ACS Infect Dis. 2021; 7 (1): 23–33. DOI: 10.1021/acsinfecdis.0c00337. PMID: 33291868.</mixed-citation><mixed-citation xml:lang="en">Rouillard K.R., Novak O.P., Pistiolis A.M., Yang L., Ahonen M.J.R., McDonald R.A., Schoenfisch M.H. Exogenous nitric oxide improves antibiotic susceptibility in resistant bacteria. ACS Infect Dis. 2021; 7 (1): 23–33. DOI: 10.1021/acsinfecdis.0c00337. PMID: 33291868.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Poh W.H., Rice S.A. Recent developments in nitric oxide donors and delivery for antimicrobial and anti-biofilm applications. Molecules. 2022; 27 (3): 674. DOI: 10.3390/molecules27030674. PMID: 35163933.</mixed-citation><mixed-citation xml:lang="en">Poh W.H., Rice S.A. Recent developments in nitric oxide donors and delivery for antimicrobial and anti-biofilm applications. Molecules. 2022; 27 (3): 674. DOI: 10.3390/molecules27030674. PMID: 35163933.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Ghaffari A., Miller C.C., McMullin B., Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide. 2006; 14 (1): 21–29. DOI: 10.1016/j.niox.2005.08.003. PMID: 16188471.</mixed-citation><mixed-citation xml:lang="en">Ghaffari A., Miller C.C., McMullin B., Ghahary A. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide. 2006; 14 (1): 21–29. DOI: 10.1016/j.niox.2005.08.003. PMID: 16188471.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ghaffari A., Neil D.H., Ardakani A., Road J., Ghahary A., Miller C.C. A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures. Nitric Oxide. 2005; 12 (3): 129–140. DOI: 10.1016/j.niox.2005.01.006. PMID: 15797841.</mixed-citation><mixed-citation xml:lang="en">Ghaffari A., Neil D.H., Ardakani A., Road J., Ghahary A., Miller C.C. A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures. Nitric Oxide. 2005; 12 (3): 129–140. DOI: 10.1016/j.niox.2005.01.006. PMID: 15797841.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Miller C.C., Rawat M., Johnson T., Av-Gay Y. Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother. 2007; 51 (9): 3364–3366. DOI: 10.1128/AAC.00347-07. PMID: 17638697.</mixed-citation><mixed-citation xml:lang="en">Miller C.C., Rawat M., Johnson T., Av-Gay Y. Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother. 2007; 51 (9): 3364–3366. DOI: 10.1128/AAC.00347-07. PMID: 17638697.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Miller C., McMullin B., Ghaffari A., Stenzler A., Pick N., Roscoe D., Ghahary A., et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide. 2009; 20 (1): 16–23. DOI: 10.1016/j.niox.2008.08.002. PMID: 18789393.</mixed-citation><mixed-citation xml:lang="en">Miller C., McMullin B., Ghaffari A., Stenzler A., Pick N., Roscoe D., Ghahary A., et al. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide. 2009; 20 (1): 16–23. DOI: 10.1016/j.niox.2008.08.002. PMID: 18789393.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Miller C.C., Hergott C.A., Rohan M., Arsenault-Mehta K., Döring G., Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros. 2013; 12 (6): 817–820. DOI: 10.1016/j.jcf.2013.01.008. PMID: 23481089.</mixed-citation><mixed-citation xml:lang="en">Miller C.C., Hergott C.A., Rohan M., Arsenault-Mehta K., Döring G., Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros. 2013; 12 (6): 817–820. DOI: 10.1016/j.jcf.2013.01.008. PMID: 23481089.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bogdanovski K., Chau T., Robinson C.J., MacDonald S.D., Peterson A.M., Mashek C.M., Wallin W.A., et al. Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease. Access Microbiol. 2020; 2 (9): acmi000154. DOI: 10.1099/acmi.0.000154. PMID: 33195983.</mixed-citation><mixed-citation xml:lang="en">Bogdanovski K., Chau T., Robinson C.J., MacDonald S.D., Peterson A.M., Mashek C.M., Wallin W.A., et al. Antibacterial activity of high-dose nitric oxide against pulmonary Mycobacterium abscessus disease. Access Microbiol. 2020; 2 (9): acmi000154. DOI: 10.1099/acmi.0.000154. PMID: 33195983.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Yaacoby-Bianu K., Gur M., Toukan Y., Nir V., Hakim F., Geffen Y., Bentur L. Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients. Pediatr Infect Dis J. 2018; 37 (4): 336–338. DOI: 10.1097/INF.0000000000001780. PMID: 28885458.</mixed-citation><mixed-citation xml:lang="en">Yaacoby-Bianu K., Gur M., Toukan Y., Nir V., Hakim F., Geffen Y., Bentur L. Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium infection in cystic fibrosis patients. Pediatr Infect Dis J. 2018; 37 (4): 336–338. DOI: 10.1097/INF.0000000000001780. PMID: 28885458.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bartley B.L., Gardner K.J., Spina S., Hurley B.P., Campeau D., Berra L., Yonker L.M., et al. High-dose inhaled nitric oxide as adjunct therapy in cystic fibrosis Targeting Burkholderia multivorans. Case Rep Pediatr. 2020; 2020: 1536714. DOI: 10.1155/2020/1536714. PMID: 32685229.</mixed-citation><mixed-citation xml:lang="en">Bartley B.L., Gardner K.J., Spina S., Hurley B.P., Campeau D., Berra L., Yonker L.M., et al. High-dose inhaled nitric oxide as adjunct therapy in cystic fibrosis Targeting Burkholderia multivorans. Case Rep Pediatr. 2020; 2020: 1536714. DOI: 10.1155/2020/1536714. PMID: 32685229.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Goldbart A., Gatt D., Tripto I.G. Non-tuberculous mycobacteria infection treated with intermittently inhaled highdose nitric oxide. BMJ Case Rep. 2021; 14 (10): e243979. DOI: 10.1136/bcr-2021-243979. PMID: 34711619.</mixed-citation><mixed-citation xml:lang="en">Goldbart A., Gatt D., Tripto I.G. Non-tuberculous mycobacteria infection treated with intermittently inhaled highdose nitric oxide. BMJ Case Rep. 2021; 14 (10): e243979. DOI: 10.1136/bcr-2021-243979. PMID: 34711619.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Sorbo L.D., Michaelsen V.S., Ali A., Wang A., Ribeiro R.V.P., Cypel M. High doses of inhaled nitric oxide as an innovative antimicrobial strategy for lung infections. Biomedicines. 2022; 10 (7): 1525. DOI: 10.3390/biomedicines10071525. PMID: 35884830.</mixed-citation><mixed-citation xml:lang="en">Sorbo L.D., Michaelsen V.S., Ali A., Wang A., Ribeiro R.V.P., Cypel M. High doses of inhaled nitric oxide as an innovative antimicrobial strategy for lung infections. Biomedicines. 2022; 10 (7): 1525. DOI: 10.3390/biomedicines10071525. PMID: 35884830.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Schairer D.O., Chouake J.S., Nosanchuk J.D., Friedman A.J. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012; 3 (3): 271–279. DOI: 10.4161/viru.20328. PMID: 22546899.</mixed-citation><mixed-citation xml:lang="en">Schairer D.O., Chouake J.S., Nosanchuk J.D., Friedman A.J. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence. 2012; 3 (3): 271–279. DOI: 10.4161/viru.20328. PMID: 22546899.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">McMullin B.B., Chittock D.R., Roscoe D.L., Garcha H., Wang L., Miller C.C. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit. Respir Care. 2005; 50 (11): 1451–1456. PMID: 16253152.</mixed-citation><mixed-citation xml:lang="en">McMullin B.B., Chittock D.R., Roscoe D.L., Garcha H., Wang L., Miller C.C. The antimicrobial effect of nitric oxide on the bacteria that cause nosocomial pneumonia in mechanically ventilated patients in the intensive care unit. Respir Care. 2005; 50 (11): 1451–1456. PMID: 16253152.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Табуйка А.В. Опыт применения плазменного воздействия в сочетании с NO-терапией при лечении хронических ран разной этиологии. Хирургия. Журнал им. Н.И. Пирогова. 2023; 10: 143–149. DOI: 10.17116/hirurgia2023101143. PMID: 37916569.</mixed-citation><mixed-citation xml:lang="en">Tabuika A.V. Experience in the use of plasma exposure with the use of NO therapy in the treatment of chronic wounds of various etiologies. Pirogov Russian Journal of Surgery = Khirurgiya. Zhurnal im. N.I. Pirogova = Khirurgiia (Mosk). 2023; 10: 143–149. (in Russ.). DOI: 10.17116/hirurgia2023101143. PMID: 37916569.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Кузнецов М.С., Насрашвили Г.Г., Панфилов Д.С., Кожанов Р.С., Пряхин А.С., Шипулин В.М., Козлов Б.Н. Влияние комбинированного метода воздушно-плазменных потоков и NO-терапии на показатели системы крови при лечении инфекционных раневых осложнений в кардиохирургии. Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка. 2021; 8 (1): 30–41. DOI: 10.25199/2408-9613-2021-8-1-30-41.</mixed-citation><mixed-citation xml:lang="en">Kuznetsov M.S., Nasrashvili G.G., Panfilov D.S., Kozhanov R.S., Pryakhin A.S., Shipulin V.M., Kozlov B.N. Influence of the combined method of air plasma flows and NO therapy on the blood system parameters in treatment of infectious wound complications in cardiac surgery. Wounds and wound infections. The journal named after prof. B.M. Kostyuchenka = Rany i Raneviye Infekcii. Zhurnal im. prof. B.M. Kostiuchenka.. 2021; 8 (1): 30–41. (in Russ.). DOI: 10.25199/2408-9613-2021-8-1-30-41.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Ачкасов Е.Е., Есипов А.В., Пекшев А.В., Мусаилов В.А. Использование аппарата генерации экзогенного монооксида азота в лечении перитонитов. Медицинская техника. 2018; 1: 47–50.</mixed-citation><mixed-citation xml:lang="en">Achkasov E.E., Esipov A.V., Pekshev A.V., Musailov V.A. The use of an apparatus for generating exogenous nitrogen monoxide in treatment of peritonitis. Medical equipment= Meditsinskaya Tehnika. 2018; 1: 47–50. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Кабисов Р.К., Шехтер А.Б., Пекшев А.В., Решетов И.В., Манейлова М.В., Николаев А.Л., Ерохов С.В., с соавт. Роль экзогенной NO-терапии в системе комплексного лечения ран и раневой патологии у онкологических больных. Российский онкологический журнал. 2000; 4: 16–22.</mixed-citation><mixed-citation xml:lang="en">Kabisov R.K., Shekhter A.B., Pekshev A.V., Reshetov I.V., Maneylova M.V., Nikolaev A.L., Erokhov S.V., et al. The role of exogenous NO therapy in comprehensive treatment system of wounds and wound pathology in cancer patients. Russian Journal of Oncology= Ross Zhurnal Oncologii. 2000; 4: 16–22. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Григорьян А.С., Грудянов А.И., Фролова О.А., Антипова З.П., Ерохин А.И., Шехтер А.Б., Пекшев А.В. Применение нового биологического фактора — экзогенного оксида азота — при хирургическом лечении пародонтита. Стоматология. 2001; 80 (1): 80–83.</mixed-citation><mixed-citation xml:lang="en">Grigoryan A.S., Grudyanov A.I., Frolova O.A., Antipova Z.P., Erokhin A.I., Shekhter A.B., Pekshev A.V. The use of a new biological factor — exogenous nitric oxide — in surgical treatment of periodontitis. Dentistry= Stomatologiya. 2001; 80 (1): 80–83. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Липатов К.В., Сопромадзе М.А., Шехтер А.Б., Емельянов А.Ю., Грачев С.В. Использование газового потока, содержащего оксид азота (NO-терапия) в комплексном лечении гнойных ран. Хирургия. 2002; 2: 41–4354.</mixed-citation><mixed-citation xml:lang="en">Lipatov K.V., Sopromadze M.A., Shekhter A.B., Yemelyanov A.Yu., Grachev S.V. The use of a gas flow containing nitric oxide (NO-therapy) in comprehensive management of purulent wounds. Surgery= Khirurgiya. 2002; 2: 41–4354. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Каменщиков Н.О., Кузнецов М.С., Дьякова М.Л., Подоксенов Ю.К., Калашникова Т.П., Тё М.А., Чурилина Е.А., с соавт. Ингаляционная терапия коморбидного пациента с COVID-19 высокими дозами оксида азота: клинический случай. Сибирский журнал клинической и экспериментальной медицины. 2022; 37 (4): 180–187. DOI: 10.29001/2073-8552-2022-37-4-180-187. DOI: 10.29001/2073-8552-2022-37-4-180-187.</mixed-citation><mixed-citation xml:lang="en">Kamenshchikov N.O., Kuznetsov M.S., Dyakova M.L., Podoksenov Yu.K., Kalashnikova T.P., Te M.A., Churilina E.A., et al. Inhalation therapy with high doses of nitric oxide in a comorbid patient with COVID-19: a clinical case. Siberian Journal of Clinical and Experimental Medicine= Sibirskiy Zhurnal Eksperimentalnoy i Klinicheskoy Meditsiny. 2022; 37 (4): 180–187. (in Russ.). DOI: 10.29001/2073-8552-2022-37-4-180-187.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Vanin A.F. Dinitrosyl iron complexes with thiol-containing ligands can suppress viral infections as donors of the nitrosonium cation (hypothesis). Biophysics (Oxf). 2020; 65 (4): 698–702. DOI: 10.1134/S0006350920040260. PMID: 33100351.</mixed-citation><mixed-citation xml:lang="en">Vanin A.F. Dinitrosyl iron complexes with thiol-containing ligands can suppress viral infections as donors of the nitrosonium cation (hypothesis). Biophysics (Oxf). 2020; 65 (4): 698–702. DOI: 10.1134/S0006350920040260. PMID: 33100351.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Wiegand S.B., Fakhr B.S., Carroll R.W., Zapol W.M., Kacmarek R.M., Berra L. Rescue treatment with high-dose gaseous nitric oxide in spontaneously breathing patients with severe coronavirus disease 2019. Crit Care Explor. 2020; 2 (11): e0277. DOI: 10.1097/CCE.0000000000000277. PMID: 33225304.</mixed-citation><mixed-citation xml:lang="en">Wiegand S.B., Fakhr B.S., Carroll R.W., Zapol W.M., Kacmarek R.M., Berra L. Rescue treatment with high-dose gaseous nitric oxide in spontaneously breathing patients with severe coronavirus disease 2019. Crit Care Explor. 2020; 2 (11): e0277. DOI: 10.1097/CCE.0000000000000277. PMID: 33225304.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Gianni S., Fenza R.D., Morais C.C.A., Fakhr B.S., Mueller A.L., Yu B., Carroll R.W., et al. High-dose nitric oxide from pressurized cylinders and nitric oxide produced by an electric generator from air. Respir Care. 2022; 67 (2): 201–208. DOI: 10.4187/respcare.09308. PMID: 34413210.</mixed-citation><mixed-citation xml:lang="en">Gianni S., Fenza R.D., Morais C.C.A., Fakhr B.S., Mueller A.L., Yu B., Carroll R.W., et al. High-dose nitric oxide from pressurized cylinders and nitric oxide produced by an electric generator from air. Respir Care. 2022; 67 (2): 201–208. DOI: 10.4187/respcare.09308. PMID: 34413210.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Goldbart A., Lavie M., Lubetzky R., Pillar G., Landau D., Schlesinger Y., Spiegel R., et al. Inhaled nitric oxide for the treatment of acute bronchiolitis: a multicenter randomized controlled clinical trial to evaluate dose response. Ann Am Thorac Soc. 2023; 20 (2): 236–244. DOI: 10.1513/AnnalsATS.202103-348OC. PMID: 36169967.</mixed-citation><mixed-citation xml:lang="en">Goldbart A., Lavie M., Lubetzky R., Pillar G., Landau D., Schlesinger Y., Spiegel R., et al. Inhaled nitric oxide for the treatment of acute bronchiolitis: a multicenter randomized controlled clinical trial to evaluate dose response. Ann Am Thorac Soc. 2023; 20 (2): 236–244. DOI: 10.1513/AnnalsATS.202103-348OC. PMID: 36169967.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Kinlin L.M., Kirchner C., Zhang H., Daley J., Fisman D.N. Derivation and validation of a clinical prediction rule for nosocomial pneumonia after coronary artery bypass graft surgery. Clin Infect Dis. 2010; 50 (4): 493–501. DOI: 10.1086/649925. PMID: 20085462.</mixed-citation><mixed-citation xml:lang="en">Kinlin L.M., Kirchner C., Zhang H., Daley J., Fisman D.N. Derivation and validation of a clinical prediction rule for nosocomial pneumonia after coronary artery bypass graft surgery. Clin Infect Dis. 2010; 50 (4): 493–501. DOI: 10.1086/649925. PMID: 20085462.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D.S., Huang X.F., Wang H.F., Le S., Du X.L. Clinical risk score for postoperative pneumonia following heart valve surgery. Chin Med J (Engl). 2021; 134 (20): 2447–2456. DOI: 10.1097/CM9.0000000000001715. PMID: 34669637.</mixed-citation><mixed-citation xml:lang="en">Wang D.S., Huang X.F., Wang H.F., Le S., Du X.L. Clinical risk score for postoperative pneumonia following heart valve surgery. Chin Med J (Engl). 2021; 134 (20): 2447–2456. DOI: 10.1097/CM9.0000000000001715. PMID: 34669637.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Chen X., Wu J., Le S., Xie F., Li X., Wang H., et al. Development and validation of nomogram models for postoperative pneumonia in adult patients undergoing elective cardiac surgery. Front Cardiovasc Med. 2021; 8: 750828. DOI: 10.3389/fcvm.2021.750828. PMID: 34708096.</mixed-citation><mixed-citation xml:lang="en">Wang D., Chen X., Wu J., Le S., Xie F., Li X., Wang H., et al. Development and validation of nomogram models for postoperative pneumonia in adult patients undergoing elective cardiac surgery. Front Cardiovasc Med. 2021; 8: 750828. DOI: 10.3389/fcvm.2021.750828. PMID: 34708096.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Huang X., Wang H., Le S, Yang H., Wang F., Du X. Risk factors for postoperative pneumonia after cardiac surgery: a prediction model. J Thorac Dis. 2021; 13 (4): 2351–2362. DOI: 10.21037/jtd-20-3586. PMID: 34012584.</mixed-citation><mixed-citation xml:lang="en">Wang D., Huang X., Wang H., Le S, Yang H., Wang F., Du X. Risk factors for postoperative pneumonia after cardiac surgery: a prediction model. J Thorac Dis. 2021; 13 (4): 2351–2362. DOI: 10.21037/jtd-20-3586. PMID: 34012584.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Wang D., Lu Y., Sun M., Huang X., Du X., Jiao Z., Sun F., et al. Pneumonia after cardiovascular surgery: incidence, risk factors and interventions. Front Cardiovasc Med. 2022; 9: 911878. DOI: 10.3389/fcvm.2022.911878. PMID: 35845037.</mixed-citation><mixed-citation xml:lang="en">Wang D., Lu Y., Sun M., Huang X., Du X., Jiao Z., Sun F., et al. Pneumonia after cardiovascular surgery: incidence, risk factors and interventions. Front Cardiovasc Med. 2022; 9: 911878. DOI: 10.3389/fcvm.2022.911878. PMID: 35845037.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">He S., Wu F., Wu X., Xin M., Ding S., Wang J., Ouyang H., et al. Ventilator-associated events after cardiac surgery: evidence from 1,709 patients. J Thorac Dis. 2018; 10 (2): 776–783. DOI: 10.21037/jtd.2018.01.49. PMID: 29607148.</mixed-citation><mixed-citation xml:lang="en">He S., Wu F., Wu X., Xin M., Ding S., Wang J., Ouyang H., et al. Ventilator-associated events after cardiac surgery: evidence from 1,709 patients. J Thorac Dis. 2018; 10 (2): 776–783. DOI: 10.21037/jtd.2018.01.49. PMID: 29607148.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Greco G., Shi W., Michler R.E., Meltzer D.O., Ailawadi G., Hohmann S.F., Thourani V.H., et al. Costs associated with health care-associated infections in cardiac surgery. J Am Coll Cardiol. 2015; 65 (1): 15–23. DOI: 10.1016/j.jacc.2014.09.079. PMID: 25572505.</mixed-citation><mixed-citation xml:lang="en">Greco G., Shi W., Michler R.E., Meltzer D.O., Ailawadi G., Hohmann S.F., Thourani V.H., et al. Costs associated with health care-associated infections in cardiac surgery. J Am Coll Cardiol. 2015; 65 (1): 15–23. DOI: 10.1016/j.jacc.2014.09.079. PMID: 25572505.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Ailawadi G., Chang H.L., O’Gara P.T., O’Sullivan K., Woo Y.J., DeRose J.J. Jr, Parides M.K., et al. Pneumonia after cardiac surgery: experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg. 2017; 153 (6): 1384–1391.e3. DOI: 10.1016/j.jtcvs.2016.12.055. PMID: 28341473.</mixed-citation><mixed-citation xml:lang="en">Ailawadi G., Chang H.L., O’Gara P.T., O’Sullivan K., Woo Y.J., DeRose J.J. Jr, Parides M.K., et al. Pneumonia after cardiac surgery: experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg. 2017; 153 (6): 1384–1391.e3. DOI: 10.1016/j.jtcvs.2016.12.055. PMID: 28341473.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Bassetti M., Righi E., Vena A., Graziano E., Russo A., Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drugresistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018; 24 (5): 385–393. DOI: 10.1097/MCC.0000000000000534. PMID: 30156569.</mixed-citation><mixed-citation xml:lang="en">Bassetti M., Righi E., Vena A., Graziano E., Russo A., Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drugresistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018; 24 (5): 385–393. DOI: 10.1097/MCC.0000000000000534. PMID: 30156569.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Mariappan S., Sekar U., Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: risk factors for infection and impact of resistance on outcomes. Int J Appl Basic Med Res. 2017; 7 (1): 32–39. DOI: 10.4103/2229-516X.198520. PMID: 28251105.</mixed-citation><mixed-citation xml:lang="en">Mariappan S., Sekar U., Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: risk factors for infection and impact of resistance on outcomes. Int J Appl Basic Med Res. 2017; 7 (1): 32–39. DOI: 10.4103/2229-516X.198520. PMID: 28251105.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Bassetti M., Carnelutti A., Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther. 2017; 15 (1): 55–65. DOI: 10.1080/14787210.2017.1251840. PMID: 27766913.</mixed-citation><mixed-citation xml:lang="en">Bassetti M., Carnelutti A., Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther. 2017; 15 (1): 55–65. DOI: 10.1080/14787210.2017.1251840. PMID: 27766913.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Igbinosa O., Dogho P., Osadiaye N. Carbapenem-resistant Enterobacteriaceae: a retrospective review of treatment and outcomes in a long-term acute care hospital. Am J Infect Control. 2020; 48 (1): 7–12. DOI: 10.1016/j.ajic.2019.07.006. PMID: 31431290.</mixed-citation><mixed-citation xml:lang="en">Igbinosa O., Dogho P., Osadiaye N. Carbapenem-resistant Enterobacteriaceae: a retrospective review of treatment and outcomes in a long-term acute care hospital. Am J Infect Control. 2020; 48 (1): 7–12. DOI: 10.1016/j.ajic.2019.07.006. PMID: 31431290.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Burillo A., Muñoz P., Bouza E. Risk stratification for multidrug-resistant Gram-negative infections in ICU patients. Curr Opin Infect Dis. 2019; 32 (6): 626–637. DOI: 10.1097/QCO.0000000000000599. PMID: 31567570.</mixed-citation><mixed-citation xml:lang="en">Burillo A., Muñoz P., Bouza E. Risk stratification for multidrug-resistant Gram-negative infections in ICU patients. Curr Opin Infect Dis. 2019; 32 (6): 626–637. DOI: 10.1097/QCO.0000000000000599. PMID: 31567570.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Corcione S., Lupia T., Maraolo A.E., Pinna S.M., Gentile I., De Rosa F.G. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Curr Opin Infect Dis. 2019; 32 (6): 663–673. DOI: 10.1097/QCO.0000000000000598. PMID: 31599774.</mixed-citation><mixed-citation xml:lang="en">Corcione S., Lupia T., Maraolo A.E., Pinna S.M., Gentile I., De Rosa F.G. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Curr Opin Infect Dis. 2019; 32 (6): 663–673. DOI: 10.1097/QCO.0000000000000598. PMID: 31599774.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y., Guo L.Y., Song W.Q., Wang Y., Dong F., Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018; 18 (1): 248. DOI: 10.1186/s12879-018-3160-3. PMID: 29855274.</mixed-citation><mixed-citation xml:lang="en">Zhang Y., Guo L.Y., Song W.Q., Wang Y., Dong F., Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018; 18 (1): 248. DOI: 10.1186/s12879-018-3160-3. PMID: 29855274.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Nicolas-Chanoine M.H., Vigan M., Laouénan C., Robert J., E-carb Study Group. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-controlcontrol study. Eur J Clin Microbiol Infect Dis. 2019; 38 (2): 383–393. DOI: 10.1007/s10096-018-3438-9. PMID: 30488368.</mixed-citation><mixed-citation xml:lang="en">Nicolas-Chanoine M.H., Vigan M., Laouénan C., Robert J., E-carb Study Group. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-controlcontrol study. Eur J Clin Microbiol Infect Dis. 2019; 38 (2): 383–393. DOI: 10.1007/s10096-018-3438-9. PMID: 30488368.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Bath P.M., Coleman C.M., Gordon A.L., Lim W.S., Webb A.J. Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. F1000Res. 2021; 10: 536. DOI: 10.12688/f1000research.51270.2. PMID: 35685687.</mixed-citation><mixed-citation xml:lang="en">Bath P.M., Coleman C.M., Gordon A.L., Lim W.S., Webb A.J. Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. F1000Res. 2021; 10: 536. DOI: 10.12688/f1000research.51270.2. PMID: 35685687.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
